Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.52 |
| ▸ | DRD4 | P21917 | 5/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 6/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577777 | 0.87 | CTSK (0.65) | CTSKDRD4SLC6A12SLC6A13CTSB | |
| SCHEMBL6577984 | 0.81 | CTSK (0.64) | CTSKDRD4SLC6A12SLC6A13CTSB | |
| SCHEMBL7483500 | 0.80 | CTSK (0.68) | CTSKCTSBCTSLCTSSCTSV | |
| SCHEMBL5099236 | 0.77 | CTSK (0.67) | CTSKCTSBCTSLCTSSCTSV | |
| SCHEMBL7052486 | 0.77 | CTSK (0.64) | CTSKCTSBCTSLCTSSCTSV | |
| SCHEMBL7052489 | 0.77 | CTSK (0.64) | CTSKCTSBCTSLCTSSCTSV | |
| SCHEMBL7052485 | 0.77 | CTSK (0.64) | CTSKCTSBCTSLCTSSCTSV | |
| SCHEMBL6580544 | 0.76 | CTSK (0.59) | CTSKCTSBCTSLCTSS | |
| SCHEMBL7407953 | 0.75 | DRD4 (0.70) | CTSKDRD4SLC6A12SLC6A13 | |
| SCHEMBL6580161 | 0.74 | CTSK (0.66) | CTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| EP-1384713-B1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885DRD4 4216/4885BCHE 1715/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | CTSK 1/4885DRD4 4619/4885BCHE 3439/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885DRD4 4216/4885BCHE 1715/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885DRD4 4216/4885BCHE 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.